EVOMMUNE INC (EVMN:NYSE)
$14.11 0.32 (2.3205%)
Analysed EVOMMUNE INC (EVMN:NYSE) News Sources
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says
10-04-2026
yahoo.com
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
24-06-2026
yahoo.com
Evommune bucked biotech IPO drought and is focused on the long game
07-04-2026
pharmavoice.com
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth
11-05-2026
yahoo.com
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
29-06-2026
yahoo.com
Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)
29-06-2026
advfn.com
Evommune terminates oral drug’s development in CSU
29-06-2026
clinicaltrialsarena.com
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
30-06-2026
yahoo.com
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
30-07-2026
yahoo.com
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
06-08-2026
yahoo.com
What is the current price of EVOMMUNE INC (EVMN:NYSE)?
The current price of EVOMMUNE INC (EVMN:NYSE) is $14.11.
EVOMMUNE INC (EVMN:NYSE) absolute price change since previous trading day?
The absolute price change of EVOMMUNE INC (EVMN:NYSE) since the previous trading day is $0.32.
EVOMMUNE INC (EVMN:NYSE) percentage price change since previous trading day?
The percentage price change of EVOMMUNE INC (EVMN:NYSE) since the previous trading day is 2.3205%.
What is the most recent average sentiment score for EVOMMUNE INC (EVMN:NYSE)?
The most recent average sentiment score for EVOMMUNE INC (EVMN:NYSE) is 46 out of 100.
What is the most recent average sentiment for EVOMMUNE INC (EVMN:NYSE)?
The most recent sentiment for EVOMMUNE INC (EVMN:NYSE) is .
SEC-8K** Filing Available For EVOMMUNE INC (EVMN:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.